Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ziopharm Oncology IN (ZIOP)

Ziopharm Oncology IN (ZIOP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 768,876
  • Shares Outstanding, K 162,553
  • Annual Sales, $ 150 K
  • Annual Income, $ -53,120 K
  • 60-Month Beta 2.74
  • Price/Sales 5,266.27
  • Price/Cash Flow N/A
  • Price/Book 12.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.08
  • Number of Estimates 3
  • High Estimate -0.06
  • Low Estimate -0.10
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.36 +5.28%
on 09/04/19
5.70 -19.47%
on 08/22/19
-0.47 (-9.29%)
since 08/16/19
3-Month
4.36 +5.28%
on 09/04/19
7.25 -36.69%
on 07/31/19
-1.13 (-19.76%)
since 06/17/19
52-Week
1.56 +194.23%
on 12/27/18
7.25 -36.69%
on 07/31/19
+1.88 (+69.37%)
since 09/17/18

Most Recent Stories

More News
Ziopharm Oncology to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, will participate in a webcast fireside chat at the Morgan Stanley 17 Annual...

MS : 44.21 (-1.21%)
ZIOP : 4.59 (-2.96%)
Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (Nasdaq: ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm's common stock...

ZIOP : 4.59 (-2.96%)
Shares of Ziopharm Oncolog Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (ZIOP , ALXN , ESPR , SAGE , CHRS )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ESPR : 36.78 (-1.66%)
ZIOP : 4.59 (-2.96%)
ALXN : 107.83 (-0.65%)
Ziopharm Oncolog Falls 2.83% on Heavy Volume: Watch For Potential Rebound

Ziopharm Oncolog (NASDAQ:ZIOP) traded in a range yesterday that spanned from a low of $4.83 to a high of $5.18. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $5.05...

ZIOP : 4.59 (-2.96%)
Ziopharm Oncology Announces Publication of Positive Results of Phase 1 Monotherapy Trial of Controlled IL-12 in Patients with Recurrent Glioblastoma in Science Translational Medicine

- Ad-RTS-hIL-12 plus 20 mg veledimex (Controlled IL-12 platform) determined to be the preferred dose

ZIOP : 4.59 (-2.96%)
SmarTrend Watching for Potential Rebound in Shares of Ziopharm Oncolog After 3.87% Loss

Ziopharm Oncolog (NASDAQ:ZIOP) traded in a range yesterday that spanned from a low of $5.42 to a high of $5.66. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $5.67...

ZIOP : 4.59 (-2.96%)
Ziopharm: 2Q Earnings Snapshot

BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Thursday reported a loss of $14.6 million in its second quarter.

ZIOP : 4.59 (-2.96%)
Ziopharm Oncology Reports Second Quarter 2019 Financial Results

- FDA Cleared IND for Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for

ZIOP : 4.59 (-2.96%)
Ziopharm Oncology Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Glioma

Ziopharm Oncology, Inc. ("Ziopharm" or "the Company") (Nasdaq: ZIOP), today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending...

ZIOP : 4.59 (-2.96%)
Ziopharm Oncology to Host Conference Call to Discuss Second Quarter 2019 Results on August 8, 2019

Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, August 8, at 8:30 a.m. ET to provide a corporate update and discuss financial...

ZIOP : 4.59 (-2.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade ZIOP with:

Business Summary

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and...

See More

Key Turning Points

2nd Resistance Point 4.85
1st Resistance Point 4.72
Last Price 4.59
1st Support Level 4.47
2nd Support Level 4.35

See More

52-Week High 7.25
Fibonacci 61.8% 5.08
Last Price 4.59
Fibonacci 50% 4.40
Fibonacci 38.2% 3.73
52-Week Low 1.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar